Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

FDA Questions Genasense's Efficacy Prior To ODAC Panel

Sep. 6, 2006

By Aaron Lorenzo

FDA examining guidance for emergency research

Sep. 6, 2006

By Aaron Lorenzo

FDA Questions Genasense's Efficacy Prior To ODAC Panel

Sep. 6, 2006

By Aaron Lorenzo

Auxilium, Oscient End Testim Pact; Auxilium Signing Lease

Sep. 6, 2006

By Aaron Lorenzo

Invitrogen Unveils Merger Plan For Sentigen: $25.9M In Cash

Sep. 5, 2006

By Aaron Lorenzo

FDA Examining Guidance For Emergency Research

Sep. 5, 2006

By Aaron Lorenzo

FDA Examining Guidance For Emergency Research

Sep. 5, 2006

By Aaron Lorenzo

Invitrogen Unveils Merger Plan For Sentigen: $25.9M In Cash

Sep. 5, 2006

By Aaron Lorenzo

Cerus Settles Class-Action Suit, Ends Headache For Management

Sep. 1, 2006

By Aaron Lorenzo

Cerus Settles Class-Action Suit, Ends Headache For Management

Sep. 1, 2006

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 9, 2025
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space
BioWorld
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of transcription (STAT)6 inhibitor KP-723 could...
GLP-1 receptor agonists continue their global victory tour
BioWorld
2024 was another banner year for GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.